• Corpus ID: 238856802

Predictive models of RNA degradation through dual crowdsourcing

  title={Predictive models of RNA degradation through dual crowdsourcing},
  author={Hannah K. Wayment-Steele and Wipapat Kladwang and Andrew M. Watkins and Do Soon Kim and Bojan Tunguz and Walter Reade and Maggie Demkin and Jonathan Romano and Roger Wellington-Oguri and John J. Nicol and Jiayang Gao and Kazuki Onodera and Kazuki Fujikawa and Hanfei Mao and Gilles Vandewiele and Michele Tinti and Bram Steenwinckel and Takuya Ito and Taiga Noumi and Shujun He and Keiichiro Ishi and Youhan Lee and Fatih {\"O}zt{\"u}rk and Anthony Chiu and Emin {\"O}zt{\"u}rk and Karim Amer and Mohamed Fares and Eterna Participants and Rhiju Das},
Messenger RNA-based medicines hold immense potential, as evidenced by their rapid deployment as COVID-19 vaccines. However, worldwide distribution of mRNA molecules has been limited by their thermostability, which is fundamentally limited by the intrinsic instability of RNA molecules to a chemical degradation reaction called in-line hydrolysis. Predicting the degradation of an RNA molecule is a key task in designing more stable RNA-based therapeutics. Here, we describe a crowdsourced machine… 

Figures and Tables from this paper


RNA secondary structure packages evaluated and improved by high-throughput experiments
A multitask-learning-based model, EternaFold, is developed, which demonstrates improved performance that generalizes to diverse external datasets, including complete viral genomes probed in vivo and synthetic designs modeling mRNA vaccines.
Theoretical basis for stabilizing messenger RNA through secondary structure design
A principled biophysical model for predicting RNA degradation is presented, and it is demonstrated that the stability of any mRNA can be increased at least two-fold over conventional design techniques, and the predicted stabilization is robust to post-design modifications.
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
The findings show that “superfolder” mRNAs can be designed to improve both stability and expression that are further enhanced through pseudouridine nucleoside modification, and provide a computational-experimental platform for the enhancement of mRNA medicines.
RNA design rules from a massive open laboratory
It is shown that the EteRNA community leveraged dozens of cycles of continuous wet laboratory feedback to learn strategies for solving in vitro RNA design problems on which automated methods fail, and show that an online community can carry out large-scale experiments, hypothesis generation, and algorithm design to create practical advances in empirical science.
Massively parallel RNA chemical mapping with a reduced bias MAP-seq protocol.
Chemical mapping methods probe RNA structure by revealing and leveraging correlations of a nucleotide's structural accessibility or flexibility with its reactivity to various chemical probes.
bpRNA: large-scale automated annotation and analysis of RNA secondary structure
Abstract While RNA secondary structure prediction from sequence data has made remarkable progress, there is a need for improved strategies for annotating the features of RNA secondary structures.
Principles for Predicting RNA Secondary Structure Design Difficulty.
In insights into specific structural features that increase the difficulty of finding sequences that fold into a target RNA secondary structure, the Eterna100 benchmark of 100 secondary structure design challenges that span a large range in design difficulty is compiled to help test future efforts.
Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution
Quantitative SHAPE reactivity information can be used to establish the secondary structure of an RNA, to improve the accuracy of structure prediction algorithms, to monitor structural differences between related RNAs or a single RNA in different states, and to detect ligand binding sites.
A Thermostable mRNA Vaccine against COVID-19
A lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (termed ARCoV) is developed and is currently being evaluated in phase 1 clinical trials.
ViennaRNA Package 2.0
New features include an expanded repertoire of tools to assess RNA-RNA interactions and restricted ensembles of structures, additional output information such as centroid structures and maximum expected accuracy structures derived from base pairing probabilities, or z-scores for locally stable secondary structures, and support for input in fasta format.